Stela Gengrinovitch, PhD
Co-founder & Chief Scientist
Your CSV is on the way
We’ve sent your CSV file to email@email.com
Claimed by
owner Add to list
BioSight
Former names:
Therapeutics for Oncology and Hematological Disorders
Stealth Mode
by Ayala Pharmaceuticals on Oct 2023 - closed due to acquisition
BioSight
BioSight Overview
Biosight is a phase-2 clinical-stage biotechnology company developing therapeutics for Hematological Malignancies and disorders.
Biosight's lead product, BST-236 (INN aspacytarabine), is a proprietary anti-metabolite designed to enable high-dose therapy with reduced systemic toxicity. BST-236 is currently being investigated as a single agent in a phase-2b trial for first-line treatment of acute myeloid leukemia (AML), following a successful and encouraging phase-1/2a trial, which demonstrated tolerability with promising efficacy in AML patients unfit for standard therapy.
Biosight's lead product, BST-236 (INN aspacytarabine), is a proprietary anti-metabolite designed to enable high-dose therapy with reduced systemic toxicity. BST-236 is currently being investigated as a single agent in a phase-2b trial for first-line treatment of acute myeloid leukemia (AML), following a successful and encouraging phase-1/2a trial, which demonstrated tolerability with promising efficacy in AML patients unfit for standard therapy.
Cumulative Funding Raised Over Time ($)
Employees Over Time
BioSight Climate Tech relevance
null
No Data, yet.
Sorry, no content found under this section.
Jul 26, 2023
www.globenewswire.com
Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement
#Acquisition #Management Changes
Nov 22, 2022
www.prnewswire.com
Biosight Launches a Phase 1/2 Clinical Trial of Aspacytarabine in Combination with Venetoclax for First-Line AML Induction Therapy, Followed by Aspacytarabine Consolidation
#Customers
Jul 6, 2021
www.globenewswire.com
Advaxis and Biosight Announce Entry into Definitive Merger Agreement
#Acquired-by #Management Changes
Dec 2, 2020
www.tmcnet.com
Biosight Closes $46M Series C Financing to Advance Clinical Oncology Programs
undefined
Aug 4, 2020
www.globenewswire.com
Biosight Granted U.S. FDA Fast Track Designation for BST-236 for the Treatment of Acute Myeloid Leukemia
#Customers #Partners
Companies you might be interested in
Driven by Finder AI
Primary sector
Total funding
Funding stage
Number of employees
Founded
Related Content
Lists. Maps. Reports
Team Members
SG
MG
RG
SE
Contact Team
Affiliated Organizations
(null)Web & social links
Locations
Israel
HaYarden St 3, Lod, Israel
Offices Abroad
Photos & videos
(0)No Data, yet.
Sorry, no content found under this section.
BioSight Business
Sector
Primary:
Health Tech & Life Sciences
Target Customer
Core Technology
Use Cases
(0)Tech Community Involvement
(0)BioSight Financials
Cumulative Funding Raised Over Time ($)
No Data, yet.
Sorry, no content found under this section.
Public Offerings & Exits
M&A
EXIT
Undisclosed
Oct 2023
Type
Merger
Merged to
Ayala Pharmaceuticals
Undisclosed
Private Equity Funding
C Round
$27M
Dec 2020
6
Investors
$27M
C Round
$19M
Mar 2020
3
Investors
$19M
B Round
$13M
May 2016
3
Investors
$13M
Undisclosed Round
$3.5M
Jul 2008
1
Investors
$3.5M
Undisclosed Round
Undisclosed
Jan 2007
1
Investors
Undisclosed
Non-Equity Funding
Mergers and Acquisitions
BioSight Lifecycle
Cumulative Funding Raised Over Time ($)
Timeline
Employees Over Time
News Over Time
No Data, yet.
Sorry, no content found under this section.
Closing Event
Oct 2023
M&A
EXIT
Undisclosed
Oct 2023
Type
Merger
Merged to
Ayala Pharmaceuticals
Undisclosed
C Round
$27M
Dec 2020
6
Investors
$27M
C Round
$19M
Mar 2020
3
Investors
$19M
B Round
$13M
May 2016
3
Investors
$13M
Undisclosed Round
$3.5M
Jul 2008
1
Investors
$3.5M
Undisclosed Round
Undisclosed
Jan 2007
1
Investors
Undisclosed
BioSight News
News Over Time
No Data, yet.
Sorry, no content found under this section.
News Articles
Jul 26, 2023
www.globenewswire.com
Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement
#Acquisition #Management Changes
Nov 22, 2022
www.prnewswire.com
Biosight Launches a Phase 1/2 Clinical Trial of Aspacytarabine in Combination with Venetoclax for First-Line AML Induction Therapy, Followed by Aspacytarabine Consolidation
#Customers
Jul 6, 2021
www.globenewswire.com
Advaxis and Biosight Announce Entry into Definitive Merger Agreement
#Acquired-by #Management Changes
Dec 2, 2020
www.tmcnet.com
Biosight Closes $46M Series C Financing to Advance Clinical Oncology Programs
undefined
Aug 4, 2020
www.globenewswire.com
Biosight Granted U.S. FDA Fast Track Designation for BST-236 for the Treatment of Acute Myeloid Leukemia
#Customers #Partners
Related Content
BioSight Team
No Data, yet.
Sorry, no content found under this section.
Employees Over Time
Companies you might be interested in
Driven by Finder AI
BioSight Internal
Create note
Notes
(undefined)
Filter notes
Content Writer
undefined
BI Verification
undefined
Phone Number
undefined
Israel Register ID
undefined
Confidence Score
undefined
Missing Fields
undefined
Profile Creator
undefined
Profile Update
undefined
undefined
Access Comprehensive Financial Analytics
Create a free account to:
- Explore detailed financial analytics.
- Track company growth and size.
- Connect with company team members.
I already have access,
I already have access,